Application of pharmaceutical composition containing anti-PD-1 antibody in preparation of drugs for treating advanced non-small cell lung cancer

Abstract

The invention provides an application of a pharmaceutical composition containing an anti-PD-1 antibody in preparation of drugs for treating advanced non-small cell lung cancer. In addition, the invention also provides a marker, a kit and a method for predicting the therapeutic effect of the pharmaceutical composition. The pharmaceutical composition comprises the anti-PD-1 antibody and a cytotoxic anticancer drug, the drug is used for treating EGFR mutant advanced non-small cell lung cancer patients, and the curative effect of the drug treated by an EGFR small molecule tyrosine kinase inhibitor is failed. The invention provides an effective treatment strategy for a patient who does not have EGFR T790M gene mutation after the EGFR mutant advanced non-small cell lung cancer fails to be treated by an EGFR small molecule tyrosine kinase inhibitor, and genome mutation and expression value efficient treatment are carried out on the patient under the treatment strategy; and the EGFR mutant advanced non-small cell lung cancer patients who can benefit from combined treatment of the anti-PD-1 antibody and the cytotoxic anticancer drugs are accurately selected, and accurate and standardized treatment of the patients is guided.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of a pharmaceutical composition containing an anti-PD-1 antibody in the preparation of a drug for treating advanced non-small cell lung cancer. Background technique [0002] Since 2004, scientists have successively discovered that EGFR gene mutations and their small molecule tyrosine kinase inhibitors (tyrosine kinase inhibitors, TKIs) are effective in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The important value of EGFR mutation in the treatment of patients with advanced NSCLC has undergone tremendous changes. The median progression-free survival (mPFS) of first-line EGFR TKIs, such as erlotinib, gefitinib, icotinib, afatinib, osimertinib and almonertinib, reaches 10-19 months. However, almost all patients with EGFR-mutant advanced NSCLC are resistant to first-line TKI therapy. After the failure of first-line TKI treatment, th...

AI Technical Summary

Problems solved by technology

However, patients with EGFR-mutant NSCLC who received single-agent PD-L1 or PD-1 antibody therapy after failure of EGFR TKIs did not show a substantial survival benefit compared with patients who received standard chemotherapy

In addition, clinical trials of combined use of EGFR TKI and PD-L1 antibodies have led to safety issues such as a high incidence of interstitial pneumonia. For patients, in addition to exploring better treatment strategies, we also need to further look for predictive markers for the efficacy of new treatment strategies, and accurately select EGFR that can benefit from the combination therapy of anti-PD-1 antibodies and cytotoxic anticancer drugs Patients with mutant advanced non-small cell lung cancer, so as to guide the precise and standardized treatment of such patients

Images